Comparison Study between MAST CLA and OPTIGEN

Kim, Jin Kook; Yoon, Yeomin; Jang, Won‐Jong; Choi, Yeon‐Joo; Hong, Seokchan; Cho, Jae Hoon

doi:10.2500/ajra.2011.25.3646

Cited by 14 publications

(17 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In order to minimize the disadvantages of in vitro tests, many companies have sought to improve the quality of their products 18. The AdvanSure™ AlloScreen is a updated version of the AdvanSure™ Allergy Screen 819.…”

Section: Discussionmentioning

confidence: 99%

Comparison of the ImmunoCAP Assay and AdvanSure™ AlloScreen Advanced Multiplex Specific IgE Detection Assay

Park

Lee

et al. 2017

Yonsei Med J

View full text Add to dashboard Cite

PurposeThe AdvanSure™ AlloScreen assay is an advanced multiplex test that allows for simultaneous detection of specific IgE (sIgE) against multiple allergens. For precise identification of causative allergens in allergic patients, we compared this new multiplex sIgE assay with the ImmunoCAP assay, which is currently the gold-standard method for sIgE detection.Materials and MethodsSerum samples from 218 Korean allergic disease patients were used to compare the ImmunoCAP and AlloScreen assays with respect to the following 13 allergens: Dermatophagoides pteronyssinus, Dermatophagoides farinae, cat and dog dander, Alternaria, birch, oak, ragweed, mugwort, rye grass, and food allergens (egg white, cow's milk, peanuts).ResultsA total of 957 paired tests using the 13 allergens were compared. The total agreement ratio ranged from 0.74 (oak) to 0.97 (Alternaria). With respect to class association analyses, the gamma index ranged from 0.819 (rye grass) to 0.990 (Alternaria). The intra-class correlation coefficients for house dust mites, cat and dog dander, Alternaria, birch, ragweed, egg white, cow's milk, and peanut sIgE titers were >0.8.ConclusionThe AlloScreen and ImmunoCAP assays exhibited similar diagnostic performance. However, due to methodological differences between the two systems, careful interpretation of their results is needed in clinical applications.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of the ImmunoCAP Assay and AdvanSure™ AlloScreen Advanced Multiplex Specific IgE Detection Assay

Park

Lee

et al. 2017

Yonsei Med J

View full text Add to dashboard Cite

show abstract

“…MAST CLA, previous version of MAST Optigen, has been reported to have slightly lower sensitivity (44.5%) than RIDA Allergy Screen (55.8%) or Polycheck Allergy (55.6%) [6]. e performance of MAST Optigen might be improved compared to MAST CLA as previous report [17].…”

Section: Discussionmentioning

confidence: 59%

“…In previous reports, the agreement between RIDA Allergy Screen and ImmunoCAP has been reported as 29.1% (kappa −0.303) on 633 discrepant sera between RIDA Allergy Screen and another MAST assay, AdvanSure system (LG Life Science, Seoul, Korea) [8]. Among 115 allergic patients, RIDA Allergy Screen showed 83.1% of agreement with ImmunoCAP for 10 common allergens [17]. Our result is similar to former one [8] because we also performed ImmunoCAP assays only on sera with discrepant results among three MAST assays.…”

Section: Discussionmentioning

confidence: 99%

“…Although, most of evaluations of performance of MAST assays were performed compared to allergen skin test [6,[13][14][15][16], comparisons with ImmunoCAP assay have been performed [5,8,17] considering the limitation of allergen skin test as a reference method due to the difference of principle of in vivo test from in vitro test [1]. ImmunoCAP assay has been known to have established performance [2].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of Multiple Allergen Simultaneous Test and ImmunoCAP for the Diagnosis of Allergic Rhinitis

Do-Youn¹,

Park²,

Hong³

et al. 2018

Korean J Otorhinolaryngol-Head Neck Surg

View full text Add to dashboard Cite

). Forty sera that tested positive with the RIDA Allergy Screen (20 for food and 20 for inhalant panel) were subjected to MAST Optigen and Polycheck Allergy. For 26 available sera with discrepant results, 62 ImmunoCAP allergen-speci�c IgE tests (Pharmacia Diagnostics, Uppsala, Sweden) were performed. Percent agreements (kappa value) were 87.6% (0.59) and 91.3% (0.60) between RIDA and MAST; 89.9% (0.55) and 88.3% (0.46) between RIDA and Polycheck; and 86.8% (0.51) and 90.6% (0.61) between MAST and Polycheck. Compared with ImmunoCAP, agreements (kappa value) of inhalant and food panels were 51.7% (0.04) and 33.3% (−0.38) for RIDA; 60.7% (0.27) and 81.8% (0.59) for MAST; and 65.5% (0.26) and 45.5% (0.07) for Polycheck. e agreements between RIDA, MAST, and Polycheck and ImmunoCAP-positivity were 45.7%, 88.2%, and 28.6%, respectively, and the agreements for ImmunoCAP-negativity were 37.0%, 51.9%, and 88.9%. MAST Optigen showed better agreement with ImmunoCAP than other assays in the food panel. Better sensitivity of MAST Optigen and better speci�city of Polycheck Allergy were suspected.

show abstract

“…Although, most of evaluations of performance of MAST assays were performed compared to allergen skin test [6, 13–16], comparisons with ImmunoCAP assay have been performed [5, 8, 17] considering the limitation of allergen skin test as a reference method due to the difference of principle of in vivo test from in vitro test [1]. ImmunoCAP assay has been known to have established performance [2].…”

Section: Discussionmentioning

confidence: 99%

Comparison of Three Multiple Allergen Simultaneous Tests: RIDA Allergy Screen, MAST Optigen, and Polycheck Allergy

Han

Shin

Park

et al. 2013

BioMed Research International

View full text Add to dashboard Cite

We compared the performances of 3 Multiple Allergen Simultaneous Test (MAST) assays: RIDA Allergy Screen (R-Biopharm, Darmstadt, Germany), MAST Optigen allergy system (Hitachi Chemical Diagnostics, Mountain View, CA), and Polycheck Allergy (Biocheck GmbH, Munster, Germany). Forty sera that tested positive with the RIDA Allergy Screen (20 for food and 20 for inhalant panel) were subjected to MAST Optigen and Polycheck Allergy. For 26 available sera with discrepant results, 62 ImmunoCAP allergen-specific IgE tests (Pharmacia Diagnostics, Uppsala, Sweden) were performed. Percent agreements (kappa value) were 87.6% (0.59) and 91.3% (0.60) between RIDA and MAST; 89.9% (0.55) and 88.3% (0.46) between RIDA and Polycheck; and 86.8% (0.51) and 90.6% (0.61) between MAST and Polycheck. Compared with ImmunoCAP, agreements (kappa value) of inhalant and food panels were 51.7% (0.04) and 33.3% (−0.38) for RIDA; 60.7% (0.27) and 81.8% (0.59) for MAST; and 65.5% (0.26) and 45.5% (0.07) for Polycheck. The agreements between RIDA, MAST, and Polycheck and ImmunoCAP-positivity were 45.7%, 88.2%, and 28.6%, respectively, and the agreements for ImmunoCAP-negativity were 37.0%, 51.9%, and 88.9%. MAST Optigen showed better agreement with ImmunoCAP than other assays in the food panel. Better sensitivity of MAST Optigen and better specificity of Polycheck Allergy were suspected.

show abstract

Comparison Study between MAST CLA and OPTIGEN

Abstract: The OPTIGEN test performed better than the MAST-CLA test for diagnosing allergic rhinitis.

Cited by 14 publications

References 9 publications

Comparison of the ImmunoCAP Assay and AdvanSure™ AlloScreen Advanced Multiplex Specific IgE Detection Assay

Comparison of the ImmunoCAP Assay and AdvanSure™ AlloScreen Advanced Multiplex Specific IgE Detection Assay

Comparison of Multiple Allergen Simultaneous Test and ImmunoCAP for the Diagnosis of Allergic Rhinitis

Comparison of Three Multiple Allergen Simultaneous Tests: RIDA Allergy Screen, MAST Optigen, and Polycheck Allergy

Contact Info

Product

Resources

About